Mezigdomide CELMoD Phase III SUCCESSOR — PatSnap Eureka
Mezigdomide SUCCESSOR Trials: BMS's Post-Revlimid CELMoD Strategy in Relapsed Myeloma
As lenalidomide faces generic erosion, Bristol Myers Squibb is advancing mezigdomide (CC-92480) through Phase III SUCCESSOR trials to redefine treatment for lenalidomide-refractory multiple myeloma. Explore the patent landscape, mechanism intelligence, and competitive signals with PatSnap Eureka.
How Mezigdomide Degrades Myeloma's Survival Machinery
Mezigdomide (CC-92480) is a next-generation cereblon E3 ligase modulator (CELMoD) engineered by Bristol Myers Squibb to achieve faster and more complete degradation of the Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors — proteins that myeloma cells depend on for proliferation and immune evasion. Unlike lenalidomide, which modulates rather than fully degrades these targets, mezigdomide's structural design drives potent neo-substrate recruitment to the CRL4-CRBN E3 ubiquitin ligase complex.
The result is a dual anti-tumour effect: direct myeloma cell death through transcription factor loss, combined with enhanced T-cell and NK-cell activation that restores immune surveillance in the bone marrow microenvironment. This mechanistic depth is the scientific rationale behind BMS's confidence in mezigdomide as a successor to lenalidomide in patients who have already been exposed to or become refractory to IMiD-based therapy.
Patent filings from BMS, tracked via PatSnap's IP analytics platform, reveal extensive structural variation claims around the CC-92480 scaffold, including combination composition claims with dexamethasone, daratumumab, and bortezomib — mirroring the SUCCESSOR trial backbone designs. Regulatory guidance from the FDA has supported accelerated development pathways for CELMoD agents in relapsed/refractory myeloma.
For life sciences teams tracking the CELMoD space, PatSnap's life sciences intelligence suite provides compound-level patent mapping, freedom-to-operate signals, and competitor filing alerts across the full cereblon modulator landscape.
SUCCESSOR-1 and SUCCESSOR-2: Trial Design and Patient Populations
BMS's SUCCESSOR programme positions mezigdomide combinations head-to-head against current standards of care in lenalidomide-exposed relapsed myeloma — a population that is rapidly growing as frontline IMiD use becomes near-universal.
| Trial | Experimental Arm | Comparator | Population | Primary Endpoint | Status |
|---|---|---|---|---|---|
| SUCCESSOR-1 | Mezigdomide + Dexamethasone + Daratumumab (MezDd) | Pomalidomide + Dexamethasone + Daratumumab (PomDd) | Relapsed/refractory MM, 1–3 prior lines, lenalidomide-exposed | Progression-Free Survival (PFS) | Enrolling |
| SUCCESSOR-2 | Mezigdomide + Dexamethasone + Bortezomib (MezVd) | Pomalidomide + Dexamethasone + Bortezomib (PomVd) | Relapsed/refractory MM, 1–3 prior lines, lenalidomide-refractory | Progression-Free Survival (PFS) | Enrolling |
| Phase I/II (MagnetisMM-3) | Mezigdomide + Dexamethasone | — | Heavily pre-treated RRMM, lenalidomide + pomalidomide refractory | Overall Response Rate (ORR) | Completed |
Track SUCCESSOR Trial Readouts in Real Time
PatSnap Eureka monitors clinical trial registries, regulatory filings, and publication databases so you never miss a mezigdomide data readout.
BMS CELMoD Patent Filing Velocity and Competitive Landscape
Patent filing activity reveals BMS's strategic intent — and signals where competitors are positioning in the cereblon modulator space. Data sourced from PatSnap Eureka's global patent database.
BMS CELMoD Patent Filing Activity (2015–2024)
Annual patent filings in the BMS CELMoD programme have grown 7× since 2015, reflecting accelerating investment in the post-Revlimid pipeline.
Relapsed Myeloma CELMoD/TPD Patent Share by Assignee
BMS holds the dominant patent position in the cereblon modulator space, with emerging competition from targeted protein degradation players.
BMS's Post-Revlimid Commercial Strategy: Why Mezigdomide Is Central
With Revlimid's patent cliff driving revenue pressure, BMS has structured its haematology pipeline around CELMoD succession — and mezigdomide is the lead asset.
Revlimid Revenue Cliff and Generic Entry
Lenalidomide (Revlimid) generated over $12 billion in peak annual revenues for BMS following the Celgene acquisition. Voluntary generic licensing agreements beginning in 2022 have progressively eroded this revenue stream, creating an urgent commercial imperative to establish a next-generation IMiD-class successor with a clean patent life.
Targeting the Lenalidomide-Refractory Population
Because lenalidomide is now embedded in frontline myeloma treatment globally — endorsed by both ASCO and ESMO guidelines — the relapsed population is increasingly lenalidomide-exposed or refractory. Mezigdomide is specifically designed to retain activity in this setting, where pomalidomide and other IMiDs show diminishing returns.
The Broader CELMoD and Targeted Protein Degradation Landscape in Myeloma
BMS is not operating in isolation. The cereblon modulator and protein degradation space is attracting significant competitive investment — with implications for SUCCESSOR's commercial positioning.
Mezigdomide (CC-92480) + Iberdomide (CC-220)
BMS holds the most advanced CELMoD pipeline, with mezigdomide in Phase III and iberdomide in Phase II/III for earlier-line myeloma and lupus. The Celgene acquisition provided BMS with the foundational cereblon biology platform, composition-of-matter patents, and clinical infrastructure that underpins both assets. PatSnap customers in pharma track BMS filing continuations quarterly.
Phase III SUCCESSOR — most advanced CELMoDARV-110 / Bavdegalutamide (PROTAC Approach)
Arvinas, partnered with Pfizer, is advancing PROTAC-based targeted protein degradation in oncology. While ARV-110 targets androgen receptor in prostate cancer, Arvinas's PROTAC platform represents a mechanistically adjacent competitive threat in the broader protein degradation space. Patent filings from Arvinas in the cereblon-adjacent E3 ligase space are tracked via PatSnap IP analytics.
PROTAC platform — E3 ligase competitionIberdomide Competitive Response + BCMA/GPRC5D Bispecifics
J&J's haematology franchise — anchored by daratumumab (Darzalex) and teclistamab — competes directly in the relapsed myeloma space where SUCCESSOR is targeting. J&J's own IMiD-class research and bispecific antibody pipeline create a multi-modality competitive environment that BMS must navigate with mezigdomide's clinical differentiation and IP position.
Bispecific + IMiD competition in RRMMDEG-35 and Covalent CELMoD Differentiation
Nurix is developing covalent CELMoD agents designed for selective and durable cereblon substrate degradation. Their pipeline, including DEG-35, represents a next-wave challenger to the BMS CELMoD franchise. Patent filings from Nurix in the cereblon modulator space have accelerated since 2021, a signal tracked in real time by PatSnap's platform for competitive intelligence teams.
Covalent CELMoD — emerging challengerMezigdomide & SUCCESSOR Trials — Key Questions Answered
Mezigdomide (CC-92480) is a next-generation cereblon E3 ligase modulator (CELMoD) developed by Bristol Myers Squibb. Unlike lenalidomide (Revlimid), mezigdomide is engineered for deeper and faster degradation of Ikaros and Aiolos transcription factors, which are critical for myeloma cell survival. This enhanced degradation potency is designed to overcome lenalidomide resistance in relapsed or refractory multiple myeloma patients.
SUCCESSOR is BMS's Phase III clinical trial programme evaluating mezigdomide-based combinations in patients with relapsed or refractory multiple myeloma. The programme includes SUCCESSOR-1 and SUCCESSOR-2, which are testing mezigdomide in combination with dexamethasone and other backbone agents against standard-of-care regimens to establish efficacy and safety in lenalidomide-exposed or refractory populations.
Revlimid (lenalidomide) generated peak annual revenues exceeding $12 billion for BMS before facing generic competition following patent expiry. As lenalidomide loses exclusivity, BMS is advancing mezigdomide as a next-generation CELMoD agent to retain leadership in the immunomodulatory drug class, address the growing population of lenalidomide-refractory myeloma patients, and establish a new commercial pillar in haematology.
The SUCCESSOR trials target patients with relapsed or refractory multiple myeloma who have received prior lines of therapy, including those who are lenalidomide-exposed or lenalidomide-refractory. This is a clinically significant and growing population given the near-universal use of lenalidomide in frontline myeloma treatment, meaning most relapsed patients have prior IMiD exposure.
CELMoD agents work by binding to cereblon, a substrate receptor of the CRL4 E3 ubiquitin ligase complex. This binding redirects the complex to degrade neo-substrates — specifically the Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors — that are essential for myeloma cell proliferation and survival. Degradation of these targets leads to anti-proliferative and immunostimulatory effects. Mezigdomide achieves faster and more complete degradation of these substrates compared to earlier IMiD agents.
BMS is the leading developer of CELMoD agents, with mezigdomide (CC-92480) in Phase III and iberdomide (CC-220) in earlier-line investigations. The broader competitive landscape includes other targeted protein degradation approaches such as PROTACs from companies including Arvinas and Nurix, as well as competing immunomodulatory strategies from Pfizer and Johnson & Johnson in the relapsed myeloma space. Patent intelligence via PatSnap Eureka can map the full filing landscape across these programmes.
Still have questions about mezigdomide or the SUCCESSOR trials? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka About MezigdomideStay Ahead of Every Mezigdomide and CELMoD Development
Join 18,000+ innovators already using PatSnap Eureka to track drug patents, clinical readouts, and competitive intelligence in real time.
References
- ClinicalTrials.gov — SUCCESSOR-1 and SUCCESSOR-2 Trial Registrations (NCT identifiers for mezigdomide Phase III)
- U.S. Food and Drug Administration (FDA) — Breakthrough Therapy and Accelerated Approval Guidance for Haematologic Malignancies
- American Society of Clinical Oncology (ASCO) — Multiple Myeloma Treatment Guidelines and Annual Meeting Abstracts
- European Society for Medical Oncology (ESMO) — Clinical Practice Guidelines: Multiple Myeloma
- Nature Medicine — CELMoD mechanism and cereblon substrate degradation research publications
- PatSnap — Global Patent Intelligence Platform: BMS CELMoD Portfolio Analysis
All patent data, filing counts, and competitive intelligence on this page are sourced from PatSnap's proprietary innovation intelligence platform and PatSnap Eureka. Clinical trial information is cross-referenced with publicly available registries. Patent share estimates are based on PatSnap Eureka landscape analysis and should be treated as indicative.
PatSnap Eureka searches patents, clinical data, and literature to answer instantly.